Dates: January 2008-December 2011

Current Position: Research Officer, Neuroscience Research Australia

Publications Generated While in the Lab:

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2

Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, Gray NS

Nat Chem Biol. 2011 Apr;7(4):203-5

LRRK2 mutations, regulation and 14-3-3 protein interaction: Implications for Parkinsons disease

Dzamko N, Alessi DR

Future Neurology. Volume 6, Issue 1, January 2011, Pages 5-8

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization

Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ

Biochem J. 2010 Sep 15;430(3):405-13

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization

Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, Ordureau A, Macartney T, Tong Y, Shen J, Prescott AR, Alessi DR

Biochem J. 2010 Sep 15;430(3):393-404

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease

Nichols RJ, Dzamko N, Hutti JE, Cantley LC, Deak M, Moran J, Bamborough P, Reith AD, Alessi DR

Biochem J. 2009 Oct 23;424(1):47-60